Anna Boggiss

Anna Boggiss

Auto-generated profile, based on publicly available information

Anna Boggiss

Rio Tinto Children's Diabetes Centre, The Kids Research Institute Australia, Perth Children's Hospital, Perth, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Journal of Psychosomatic Research
Verified
Journal Article
Closed access
ABAnna L. Boggiss
Anna L. Boggiss
NCNathan Consedine
Nathan Consedine
JBJennifer Brenton-Peters
Jennifer Brenton-Peters
PHPaul L. Hofman
Paul L. Hofman
ASAnna S. Serlachius
Anna S. Serlachius

1 November 2021 in Journal of Psychosomatic Research
Verified
Journal Article
Closed access
JBJennifer Brenton-Peters
Jennifer Brenton-Peters
NCNathan Consedine
Nathan Consedine
ABAnna Boggiss
Anna Boggiss
KWKate Wallace-Boyd
Kate Wallace-Boyd
Rajshri RoyRajshri Roy
Rajshri Roy
ASAnna Serlachius
Anna Serlachius

2 July 2020 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
ABA. L. Boggiss
A. L. Boggiss
NCNathan Consedine
Nathan Consedine
KSK. R. Schache
K. R. Schache
CJC. Jefferies
C. Jefferies
KBK. Bluth
K. Bluth
ASA. S. Serlachius
A. S. Serlachius

5 May 2023 in JMIR Diabetes
Verified
Journal Article
Open access
ABAnna Boggiss
Anna Boggiss
NCNathan Consedine
Nathan Consedine
SHSarah Hopkins
Sarah Hopkins
CSConnor Silvester
Connor Silvester
CJCraig Jefferies
Craig Jefferies
ASAnna Serlachius
Anna Serlachius
Background: Before the COVID-19 pandemic, adolescents with type 1 diabetes (T1D) had already experienced far greater rates of psychological distress than their peers. With the pandemic further challenging mental health and increasing the barriers to maintaining optimal diabetes self-management, it is vital that this population has access to remotely deliverable, evidence-based interventions to improve psychological and diabetes outcomes. Chatbots, defined as digital conversational agents, offer these unique advantages, as well as the ability to engage in empathetic and personalized conversations 24-7. Building on previous work developing a self-compassion program for adolescents with T1D, a self-compassion chatbot (COMPASS) was developed for adolescents with T1D to address these concerns. However, the acceptability and potential clinical usability of a chatbot to deliver self-compassion coping tools to adolescents with T1D remained unknown. Objective: This qualitative study was designed to evaluate the acceptability and potential clinical utility of COMPASS among adolescents aged 12 to 16 years with T1D and diabetes health care professionals. Methods: Potential adolescent participants were recruited from previous participant lists, and on the web and in-clinic study flyers, whereas health care professionals were recruited via clinic emails and from diabetes research special interest groups. Qualitative Zoom (Zoom Video Communications, Inc) interviews exploring views on COMPASS were conducted with 19 adolescents (in 4 focus groups) and 11 diabetes health care professionals (in 2 focus groups and 6 individual interviews) from March 2022 to April 2022. Transcripts were analyzed using directed content analysis to examine the features and content of greatest importance to both groups. Results: Adolescents were broadly representative of the youth population living with T1D in Aotearoa (11/19, 58% female; 13/19, 68% Aotearoa New Zealand European; and 2/19, 11% Māori). Health care professionals represented a range of disciplines, including diabetes nurse specialists (3/11, 27%), health psychologists (3/11, 27%), dieticians (3/11, 27%), and endocrinologists (2/11, 18%). The findings offer insight into what adolescents with T1D and their health care professionals see as the shared advantages of COMPASS and desired future additions, such as personalization (mentioned by all 19 adolescents), self-management support (mentioned by 13/19, 68% of adolescents), clinical utility (mentioned by all 11 health care professionals), and breadth and flexibility of tools (mentioned by 10/11, 91% of health care professionals). Conclusions: Early data suggest that COMPASS is acceptable, is relevant to common difficulties, and has clinical utility during the COVID-19 pandemic. However, shared desired features among both groups, including problem-solving and integration with diabetes technology to support self-management; creating a safe peer-to-peer sense of community; and broadening the representation of cultures, lived experience stories, and diabetes challenges, could further improve the potential of the chatbot. On the basis of these findings, COMPASS is currently being improved to be tested in a feasibility study.

18 May 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
HTHiran Thabrew
Hiran Thabrew
ABAnna Lynette Boggiss
Anna Lynette Boggiss
DLDavid Lim
David Lim
KSKiralee Schache
Kiralee Schache
EMEva Morunga
Eva Morunga
ASAnna Sofia Serlachius
Anna Sofia Serlachius
Objectives To evaluate the efficacy and acceptability of ‘Whitu: seven ways in seven days’, a well-being application (app) for young people. Design Prospective randomised controlled trial of Whitu against waitlist control, with 45 participants in each arm. Participants 90 New Zealand young people aged 16–30 recruited via a social media advertising campaign. Setting Participants’ homes. Interventions Developed during the COVID-19 pandemic, and refined from a prototype version that was evaluated during a smaller qualitative study, ‘Whitu: seven ways in seven days’ is a well-being app that, as its name suggests, contains seven modules to help young people (1) recognise and rate emotions, (2) learn relaxation and mindfulness, (3) practice self-compassion and (4) gratitude, (5) connect with others, (6) care for their physical health and (7) engage in goal-setting. It can be completed within a week or as desired. Main outcome measures Primary outcomes were changes in well-being on the WHO 5-item Well-Being Index and Short Warwick-Edinburgh Mental Well-Being Scale. Secondary outcomes were changes in depression on the Centre for Epidemiological Studies Depression Scale, anxiety on the Generalised Anxiety Disorder 7-item Scale, self-compassion on the Self Compassion Scale-Short Form, stress on the 10-item Perceived Stress Scale, sleep on the single-item Sleep Quality Scale and user engagement on the end-user version of the Mobile Application Rating Scale and via qualitative feedback during an online survey. Outcomes were evaluated at baseline, 4 weeks (primary study endpoint) and 3 months, and analysed using linear mixed models with group, time and a group–time interaction. Results At 4 weeks, participants in the Whitu group experienced significantly higher emotional (Mean difference (md) 13.19 (3.96 to 22.42); p=0.005) and mental (md 2.44 (0.27 to 4.61); p=0.027) well-being, self-compassion (md 0.56 (0.28 to 0.83); p<0.001) and sleep (md 1.13 (0.24 to 2.02); p=0.018), and significantly lower stress (md −4.69 (−7.61 to –1.76); p=0.002) and depression (md −5.34 (−10.14 to –0.53); p=0.030), compared with the waitlist controls. Group differences remained statistically significant at 3 months for all outcomes. Symptoms of anxiety were also lower in the intervention group at 4 weeks (p=0.096), with statistically significant differences at 3 months (md −2.31 (−4.54 to –0.08); p=0.042). Usability of Whitu was high (subjective ratings of 4.45 (0.72) and 4.38 (0.79) out of 5 at 4 weeks and 3 months, respectively) and qualitative feedback indicated individual and cultural acceptability of the app. Conclusions Given the evolving psychological burden of the COVID-19 pandemic, Whitu could provide a clinically effective and scalable means of improving the well-being, mental health and resilience of young people. Replication of current findings with younger individuals and in other settings is planned. Trial registration number Australian New Zealand Clinical Trials Registry (ACTRN12620000516987).

30 April 2021 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
ABAnna L. Boggiss
Anna L. Boggiss
NCNathan Consedine
Nathan Consedine
KSKiralee R. Schache
Kiralee R. Schache
KWKate Wallace‐Boyd
Kate Wallace‐Boyd
NCNicholas Cao
Nicholas Cao
ASAnna S. Serlachius
Anna S. Serlachius